Our Research Journey

Re-Imagine Aging with full cardiovascular health,

feeling capable and feeling good.

There are many ways to attack the issues of cardiovascular health as the aging process progresses: figuring-out the meticulous pathological details that are present in older people and trying to medically/scientifically work it backwards. Our research on NanobacTX shows that we're not only able to maintain cardiovascular function but help improve heart health and vascular function from head-to-toe.....keeping optimal bloodflow to virtually everything and making all function more effectively and youthfully. Our Nanobiotics are proprietary non-prescription compounds designed to regenerate human organs and tissues and improve vascular health. For example, our flagship Nanobiotic: NanobacTX is a patented non-prescription compound that is used by cardiologists and other physicians in their practices to assist patients in the maintenance of their cardiovascular health. NanobacTX does not require a prescription and you can purchase it now through this website.

"OUR JOURNEY has been long and arduous, yet we've a long way to reach our goals. You will see from the scientific & clinical trials publications listed at the bottom of the NanobacTX and Urobac pages, that we've been very busy since I started all of this. We have developed a great deal of published science and clinical trials with top-notch researchers all over the World."
~Gary S. Mezo, Founder, Chairman & CEO
EMail: info@NanoBiotechPharma.com

Coronary Artery Calcification and the Development of Vulnerable Plaques. - Mezo, GS

Coronary Artery Calcification (CAC) and extra-vascular pathological calcification is secondary to an infection by Nanobacteria (also known as CNPs, NPs or NB). CNPs cause calcification and inflammation response from their exudate, a lipopolysaccharide biofilm (LPS). CNPs oxidize LDL and VLDL cholesterol as food in their regeneration-cycle. CNPs have 2 pleomorphic modes of growth: fast (replication every 3 days) which involves LPS Biofilm; and slow (replication every 6 days) that involves the development of protective calcium layers "igloos" around themselves. When locked in the intimal-medial space of an artery, these CNPs are temporarily deprived of their food which is VLDL/LDL cholesterol from blood. In this slow-replication mode, CNPs build layers of calcification upon themselves, building an intimal-medial "igloo" around themselves as a bolus of calcification. As our immune system tries to wall-off the area of CNP infection (like a cyst), the area is covered with amyloid soft plaque. This soft plaque temporarily stabilizes the plaque-lesion. After a while, our immune system recognizes the area as non-threatening and inactive and then does what it normally does to a walled-off area of infection, it works to regenerate and debulk the area by initiating the process of neovascularization. Through this process of neovascularization, new microscopic blood vessels bring fresh blood containing VLDL & LDL to the area. Now the CNPs have their required nutrients of VLDL & LDL cholesterol. When re-supplied with their food, the CNPs switch to fast replication again and form LPS biofilm. This biofilm causes inflammation and our immune system now fights the infection all over again.....causing the process to repeat itself....now the area is red and swollen. This is the "vulnerable plaque" phase. These inflammatory episodes wax and wane until such time that the calcified plaque burden is so large that it can inflame the area, impair blood flow from swelling and can rupture into the lumen of the blood vessel like the "popping of a pimple". Once CNPs are expelled from the ruptured plaque into the blood stream, they immediately bind prothrombin, causing a blood clotting cascade....this leads to MI (Heart Attack). We at NanoBiotech Pharma have developed nanobiotics (NanobacTX & Urobac) to deal with these effects. Author's disclosure (Jan 18, 2012) - Our researchers discovered CNPs and we direct Nanobacteria, CNPs & NPs endovascular research Worldwide.

A great independently-assessed summary of research is here: Anton Kutikin, PhD in The International Journal of NanoMedicine "The Role of CNPs in Biology & Medicine" www.ncbi.nlm.nih.gov/pmc/articles/PMC3266001

[Please note: 1) For publishing purposes, our Nanobiotics were referred-to as comET a generic name and not actual trademarks of NanobacTX or Urobac. Scientific publications allow only the use of generic names and not trademarks. 2) Our researchers at Mayo Clinic, Drs. Cockerill, Lieske & Miller refer to Nanobacteria & CNPs as NPs in their published research. Other published researchers have referred to them as NB, NP and Bions.]

After discovery, Nanobacteria (CNPs) was originally filed as Nanobacterium sanguineum (Blood Nanobacteria), also in the past referred to as Nanobacteria, Nb, Calcifying NanoParticles, CNPs and NPs. Research has categorized CNPs as a new and unique non-bacterial, non-viral, non-prion self-replicating human infectious agent that is ubiquitous. CNPs are not alive, at least not by the current strict microbiology definition requirements of "living", yet they do self-reproduce under normal living human and mammalian physiologic conditions. CNPs are actively involved in the development of many chronic calcification-related diseases that threaten both health and life. Although nanometer-sized, they are a big concern. The medical implications of CNPs are huge and our discoveries are potentially disruptive to current medical pathology knowledge. Unfortunately, new and potentially disruptive technologies are very slowly adopted into mainstream medical practice. The average time for adoption of such discoveries or paradigm shifts is 15-20 years.

CNP Size: 25-200 Nanometers. CNPs are the smallest known self-replicating entity. CNPs are proposed as a newly-discovered form of life or entity as an infectious agent. Smaller than current size standards for "living" entities, they appear to cause life-long challenges in humans and other mammals. (Of note: Viruses and Prions are not considered as living entities, yet their disease-causing behavior is well-known & documented). CNPs cannot be seen using regular laboratory light microscopes and therefore have escaped scientific description and clinical detection until discovered by Kajander. At 25-200 nanometers, CNPs are thousands of times too-small to be seen under any laboratory or clinical microscopes. CNPs can only be observed under electron microscopes, atomic force microscopes and more recently using the novel CytoViva hyper-spectral microscopy imaging system that can resolve living things as small as 10 nanometers (1 nanometer = 1 billionth of a meter).

CNPs Grow Very Slowly, reproducing every 3-6 days instead of in seconds or minutes like bacteria or viruses.

CNPs are very tough to eradicate In Culture & In Humans. They are extremely resistant to destruction, including: penicillins, cephalosporins, macrolides, acids, heat, freezing, nanocolloidal silver & radiation. CNPs easily circumvent & defeat our immune defense systems and cause apoptosis (cell death) and alter RNA & DNA replication. Yet they appear to be addressed with our Nanobiotics: NanobacTX & Urobac.

CNPs appear to be the active cause of all pathological (disease-related) calcification: They are pleomorphic and have several lifestyles: a calcific semi-dormant form and a slimy biofilm form. They form a calcium apatite lipopolysaccharide (LPS) biofilm endotoxin that causes inflammation, tissue swelling, apoptosis & thrombus formation.

HISTORY: CNPs were discovered by accident by our Finnish researcher and Nobel Prize Nominee (2000), Olavi Kajander, MD, PhD as a contaminant of mammalian cell cultures. His cell cultures kept routinely dying after a period of time. Kajander investigated further and discovered that it was CNPs infecting his cell cultures and killing them through the process of cellular apoptosis. Kajander called them Nanobacteria because they are nanometer-sized. They ranged from 25-200 nanometers in size and are the smallest known self-replicating infectious pathogen.

Their nanometer-size and their use of calcium allows them to "trick" our cellular defense mechanisms, moving through cell walls to directly invade the nucleus of our cells and alter RNA/DNA replication processes. They cause apoptosis (cell death) when exposed to the nucleus of cells in human cells, mammalian cells and in other bacteria. Altering RNA and DNA gene-expression patterns can lead to apoptosis, genetic alteration of the cell, abnormal cell growth, excess cell proliferation and cancer. Documented by our researchers, CNPs have a unique helical double cell membrane that has never been seen before in any other entity.

Challenges caused by CNPs have only recently been discovered. CNPs other effects are still being researched and described. CNPs require BSL-3 level containment in research facilities. DNA, RNA and LPS genomic profiles have been mapped by multiple scientific researchers at many facilities worldwide. CNPs provide no known positive benefits to humans or other mammals.

CNPs utilize serum calcium and LDL to manufacture pathological calcification deposits under normal serum/blood calcium conditions. Prior to the discovery of CNPs, science has not been able to explain how such calcification is possible. Previously, scientists just accepted the unexplainable disease-related calcification development in our bodies as a mysterious unknown phenomenon of "aging".

Aside from being toxic on their own, CNP's calcium-phosphate slimy LPS endotoxin biofilm layer actively binds other proteins that are involved in many diseases and can directly cause the process of thrombosis (blood clotting) when expelled or exposed to the blood stream.

CNPs have been detected and isolated in virtually all human organs and systems and do cross the blood-brain barrier. They have been seen as calcification or uncalcified forms in urine and kidney stones, bile and gall bladder stones, atherosclerotic plaque, cataracts, Alzheimer's disease, vascular dementia, heart valves, PKD cysts, liver cysts, fibromyalgia, fetal bovine serum, viral vaccines, cancers, prostate stones, testicular stones, BPH, prostatitis, eczema, psoriasis, scleroderma, atopic dermatitis, brain sand, pineal & pituitary calcification and many others. Many prominent researchers agree that pathological calcification is caused by CNP infections wherever they are found in the human system.

CNPs directly cause or participate in many pathological events such as inflammation, endovascular neovascularization, thrombosis, chronic autoimmune activation, cell proliferation, altered cell functions, pathological calcification, apoptosis and subsequent tissue and organ system atrophy.

Our collaborators at Mayo Clinic's Infectious Disease, Cardiology & Nephrology research teams have shown in many published research papers that CNPs play an active role in the development of atherosclerosis and coronary artery disease, heart valve calcification, kidney stones, PKD and many other diseases previously described as of unknown or unexplainable origin.......now directly attributed to CNP infections.

Research conducted by endovascular researcher Stephen Epstein, MD, PhD (Former Director of NIH Cardiovascular Research) at Washington Hospital Center in Washington, DC found in his studies: 1) "Nanobacterial Epidemiology, Inflammatory Markers and Coronary Artery Calcification in Asymptomatic Presumed Normal Patients" and 2) "Nanobacterial Epidemiology, Inflammation & Coronary Artery Disease Risk" that Nanobacteria (aka CNPs) are the greatest known cardiovascular risk factor for coronary artery calcification (CAC) and Coronary Artery Heart Disease and are the strongest predictor ever found in predicting the risk of having a future heart attack.

Research at the Cleveland Clinic, UCSF, Baylor, U of I and NASA has also documented Nanobacteria's causative involvement in the development of Prostate Disease, BPH, Ovary Disease, Interstitial Cystitis, Polycystic Kidney Disease & Kidney Stones.

We are the World's leading experts on Nanobacteria. We have either conducted, directed or stimulated all of the research on Nanobacteria (CNPs/NPs) leading to scores of published scientific papers by a broad global network of our collaborating scientists & researchers. We developed the only nanobiotics: NanobacTX & Urobac to affect CNPs. Our non-prescription nanobiotics are safe, as shown in published clinical trials by respected physician-specialists, are nutraceutical-based and are available now.